AMPIVIEW® RNA probes
Enabling Your Projects 
GMP Services
Bulk Solutions
Research Travel Grant
Have You Published Using an Enzo Product?
Enzo Therapeutics
Overview
Enzo Therapeutics, a biopharmaceutical subsidiary of Enzo Biochem (ENZ:NYSE), designs and develops enabling platforms based on immune and genetic regulation. These platforms offer multiple approaches for the treatment of a variety of diseases. The Company has focused its efforts in the areas of gastrointestinal, infectious, ophthalmic and metabolic diseases, and cancer. Many of the promising therapeutic applications currently under development are derived from pioneering work initiated at Enzo Life Sciences.
Enzo has concentrated its development on treatment regimens for diseases and conditions for which current treatment options are ineffective, costly, and/or cause unwanted side effects. Our focused efforts have generated a clinical and preclinical pipeline that is strongly supported by more than 40 patents and patent applications.
Enzo Therapeutics has established mutually rewarding, long-term relationships with academic institutions and enjoys a positive synergy with the Company’s other two subsidiaries, Enzo Life Sciences and Enzo Clinical Labs.
Our Mission
To design broad enabling technology platforms for the development of therapeutic products that target difficult-to-treat diseases and conditions in the areas of gastrointestinal, infectious, ophthalmic diseases, metabolic diseases and cancer.
Our Strategy
Enzo Therapeutics intends to exploit its broadly applicable and innovative technology platforms to develop products for treating a variety of diseases.
The broad diagnostic and therapeutic potential offered by Enzo’s core technology platforms extend to applications well beyond those currently under development in-house.
For additional therapeutic applications that will not be developed in-house, Enzo seeks collaborations or partnerships with other companies that can provide a synergistic enhancement of drug development.
Our Technologies and Pipeline
Enabling Immune Regulation
Many pathological conditions stem from deregulation of the immune system. Enzo has developed proprietary technology in two areas of immune regulation: Oral tolerance and Immune modulation
Enabling Gene Technology
Enzo Therapeutics has developed an approach for highly specific gene regulation. This technology, known as genetic antisense or antisense RNA, utilizes a gene that codes for an RNA molecule that specifically inhibits the messenger RNA product of a specific gene. The antisense gene is delivered to the target cell ex vivo (outside the body) using a virus vector in a process called transduction. For efficient gene delivery Enzo scientists have developed a gene delivery vehicle, the StealthVector® HGTV43T transducing vector, that offers the following advantages for providing broad applicability in the field of gene medicine.
Enabling Cell Signaling Modulation
Enzo’s therapeutic platform provides a basis for the development of pharmaceutical agents that modulate protein-protein interactions. Our scientists and collaborators have unlocked the secrets of a major cell signaling pathway and developed a means to modify biologic activity in several metabolic systems through the use of small molecule drug candidates.